Can New Generation GLP-1s Overcome The Adherence Hurdle?
Historically, Patients Have Not Tended To Stay On These Drugs Long-Term
Executive Summary
Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term.
You may also be interested in...
Structure Emerges In Obesity Race With Oral GLP-1 Agonist
Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.
English Funding Nod For Lilly’s Diabetes GLP-1 Mounjaro, Roche’s Cancer MAb Columvi
Eli Lilly’s new type 2 diabetes injectable treatment Mounjaro is the latest GLP-1 to secure reimbursement in England following a positive opinion from HTA body NICE. Roche’s lymphoma drug Columvi and a new indication for UCB’s Bimzelx were also backed in recent draft guidance.
Value Versus Headcount: What Do The Numbers Show?
Increases in employee numbers often go hand-in-hand with valuation rises as companies are acquired or product success demand increases in sales staff or manufacturing capacity. However, this is not always the case.